| Chemical Information | |
| Antiviral agent ID | DrugRepV_3658 | |
| Antiviral agent name | 2-(4-methylphenyl)-4-(trifluoromethyl)-3H-1,5-benzodiazepine | |
| IUPAC Name | 2-(4-methylphenyl)-4-(trifluoromethyl)-3H-1,5-benzodiazepine |  |
| SMILES (canonical) | CC1=CC=C(C=C1)C1=NC2=CC=CC=C2N=C(C1)C(F)(F)F | |
| Molecular Formula | C17H13F3N2 | |
| Molecular Weight (g/mol) | 302.3 | |
| InChl | InChI=1S/C17H13F3N2/c1-11-6-8-12(9-7-11)15-10-16(17(18,19)20)22-14-5-3-2-4-13(14)21-15/h2-9H,10H2,1H3 | |
| Structural Information | |
 |
|
| Clinical Information | |
| Biological Information | |
|
Secondary Indication | Ebola virus (EBOV) NA NA |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | 293T
| |
|
Secondary Indication (Mode of viral infection) | Transfection
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | Post infection
| |
|
Secondary Indication (Duration of drug delivery) | 48 hours
| |
|
Secondary Indication (Drug concentration) | 75.7 μM
| |
|
Secondary Indication (Cell based assay) | Luciferase assay
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | IC90 [ 90 % ] | |
|
Secondary Indication (Cytotoxicity) | 73.4 μM | |
|
Reference | Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I, Moir DT, Bavari S, Ray R, Farzan MR, Rong L, Bowlin TL..Identification of a small-molecule entry inhibitor for filoviruses..J Virol. 2011 Apr;85(7):3106-19. doi: 10.1128/JVI.01456-10. Epub 2011 Jan 26. PubMed Central PMCID: PMID:21270170
|  |
|
Comment | A benzodiazepine derivative (compound 7) was identified from a high-throughput screen (HTS) of small-molecule compound libraries utilizing the pseudotype virus.
| |